<DOC>
	<DOC>NCT01297543</DOC>
	<brief_summary>Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this study, the safety, tolerability and activity of CLT-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD), neutrophil and platelet recovery, hMPC persistence, infections and complications.</brief_summary>
	<brief_title>Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Key Hematological malignancy, including: AML, ALL or MDS Planned treatment with cytarabinebased chemotherapy regimen Adequate hepatic, renal, hematologic, cardiac and respiratory function Key Prior allograft or history of active GVHD within 3 years Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Re-induction chemotherapy</keyword>
	<keyword>Consolidation chemotherapy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplasia</keyword>
</DOC>